Jordan Food & Drug Administration. Pharmaceutical Policy Studies Workshop RUD Unit Plan for RUD Unit.

Slides:



Advertisements
Similar presentations
Step 4: Strategy Implementation. Learning Objectives Understand the elements and benefits of developing an action plan Value the involvement of internal.
Advertisements

Strategies to Improve Efficiency in Medicine Procurement Towards equitable and affordable medicine prices policies in Jordan Workshop 4-5 Dec, 2007 Dr.
WHO STRATEGY FOR WORKING WITH COUNTRIES:REGIONAL AND COUNTRY PERSPECTIVE TECHNICAL BRIEFING SEMINAR,Geneva,19-23 September 2005 Dr. Jean-Marie TRAPSIDA.
FUNCTION OF MEDICAL COUNCIL AND ITS IMPORTANCE IN PPP PROMOTION H.E. Professor Thir Kruy, Secretary of State, MoH President of MCC Intercontinental Hotel.
World Health Organization
Promoting Rational Use of Injections within National Medicine Policies World Health Organisation Dept. Essential Drugs and Medicines Policy Safe Injection.
Presentation by Cambodian Participants Phuket, Thailand February 2012 Health Impact Assessment Royal Government of Cambodia.
Project Advisory Committee Meeting 26th June 2012, New Delhi Vikash Batham CUTS International Exploring the Interplay between Business Regulation and Corporate.
INITIATING THE PLANNING PROCESS. CONTENT Outputs from this stage Stage general description Obtaining government commitment Raising awareness Establishing.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
GHS Conference for ASEAN Implementation Towards 2008 and Beyond 9-11 May 2007,Yakarta, Indonesia By: Lao Delegates Vientiane Capital City, Lao PDR.
EARLY CHILDHOOD EDUCATION
Session 4: Good Governance: How SAIs influence Good Governance in Public Administration Zahira Ravat 27 & 28 May 2014.
EDM STRATEGY FOR WORKING WITH COUNTRIES-TANZANIA Rose Shija EDM NPO TANZANIA.
NATIONAL STRATEGY FOR WSP IMPLEMENTATION IN GHANA. Nii Okai Kotei Director, Water Public Utilities Regulatory Commission, Accra, GHANA IWA Africa Region.
National Medicine Policy
World Breastfeeding Trends Initiative (WBTi) Assessment of the Status of Global Strategy for Infant and Young Child Feeding at National Level — achievements.
General presentation. 24 March 2003 | | ‹#› Overall objective Main objective To develop and improve preventive and health-promoting efforts and the services.
Orienting Extension Faculty that are Volunteer Administrators.
MeTA Jordan Executive Summary Baseline data is an important source for policy makers to diagnose the pharmaceutical and health sector situation in order.
Children’s Mental Health: An Urgent Priority for Illinois.
Pharmacovigilance Programme of India
Wilbert Bannenberg SARPAM
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Tanzania1. 2 Tanzania Assessment Gabriel Upunda Tanzania3 DemographicsTanzania Area (sq km)945,100 Population 32,900,000 25% urban GNP per capitaUS $240.
INITIATING THE PLANNING PROCESS. CONTENT Outputs from this stage Stage general description Obtaining government commitment Raising awareness Establishing.
MALAWI GOVERNMENT MINISTRY OF HEALTH PROGRESS ON GOOD GOVERNANCE IN THE PHARMACEUTICAL SECTOR IN MALAWI By Dr Charles Mwansambo Secretary for Health 20.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
BASELINE SURVEYS AND MONITORING OF PHARMACEUTICAL SITUATION IN COUNTRIES. Joseph Serutoke NPO/EDM WHO Uganda November 2002.
Promoting Drug and Therapeutics Committees in the Developing World
PUBLIC UTILITIES REGULATORY COMMISSION OF GHANA CONSUMER EDUCATION A PRESENTATION BY CONSUMER SERVICES DIRECTORATE.
Improving of maternal and neonatal health Prof d-r Elizabeta Zisovska.
Capacity Building for the Kosovo Anti- Corruption Agency Constantine Palicarsky.
PUBLIC INTERNAL CONTROL (PIC) SYSTEM OF HUNGARY Ms. Edit NÉMETH CENTRAL HARMONISATION UNIT FOR PUBLIC INTERNAL CONTROL, HUNGARY BUDAPEST, 25 TH OF JUNE,
The Malawi Experience: - with a focus on donor coordination Paper presented at the PARIS21/SADC meeting on NSDS and RSDS in Maputo – October 14, 2013 by.
CHAPTER V Health Information. Updates on new legislation (1)  Decision No.1605/2010/QĐ-TTg approving the National Program for Application of information.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Group 2 GROUP 2. Outline Who are the stakeholders How do we create awareness Accessibility How do we promote R&D.
Juanita Folmsbee, Country Project Director, SIAPS program Feedback related to Pharmaceutical Sector.
HEALTH FINANCING MOH - HPG JAHR UPDATE ON POLICIES Eleventh Party Congress -Increase state investment while simultaneously mobilizing social mobilization.
1 Strategic Plan Review. 2 Process Planning and Evaluation Committee will be discussing 2 directions per meeting. October meeting- Finance and Governance.
WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.
Overview of The Submission to the Ministry of Health and Long-Term Care In Response to Technical Fee Reimbursement in Ontario And a Request to Form a Technical.
MONITORING THE PHARMACEUTICAL SECTOR IN A DEVELOPING COUNTRY - THE GHANA EXAMPLE Gyansa-Lutterodt M. 1,7, Andrews E 2, Arhinful D 3,7, Addo-Atuah J 4,7,
1 PORTFOLIO COMMITTEE ON MINERAL RESOURCES DISCUSSION ON THE MINERAL RESOURCES 2014 / 15 STRATEGIC PLAN 8-9 July 2014 Programme 2: Mine Health and Safety.
HELWAN UNIVERSITY Faculty of engineering Biomedical department Hospitals Organization and administrative structure :Presented by : Sara Mousa Ismail Dr\Mohammed.
ADDRESSING PHARMACEUTICAL SUPPLY CHAIN NEEDS PRESENTATION TO HEALTH DONOR GROUP MEETING 8 July 2009.
Regional, District Leadership and Facility Pediatric Quality Improvement Teams (PQITs) as Champions of Implementation Sustainability 3rd NQIF 26th - 28th.
Jordan Food & Drug Administration Administration.
EDM Strategy for Working with Countries: the Uganda Example
Health systems research at the University of Botswana: Working with the MoH Oathokwa Nkomazana.
National Health Strategy
CDA PRESENTATION TO PORTFOLIO COMMITTEE ON SOCIAL DEVELOPMENT 2005/03/09 PROF RATAEMANE.
Wilbert Bannenberg SARPAM
Promoting Drug and Therapeutics Committees in the Developing World
WHO Medicines Work in Countries: The Kenya Example
Pharmacy and Therapeutics Committees in Thai Hospitals under Health Reform Sripairoj A, Liamputtong P, Harvey K La Trobe University, Australia.
Kode Etik dan IA Standard Dr Rilla Gantino, SE., AK., MM
Richard Laing EMP/WHO TBS 2012
Jordan Food & Drug Administration
A 10-year Plan Presented by: Andrea Ridgway, MS, RD, LD, CDE
Lessons Learned and Recommendations
Implementation: the Case of Egypt
National Medicines Policies
A good practice of harmonisation between reforms: public internal control and anti-corruption Edit Németh, Head of CHU Ministry of Finance.
Richard Laing WHO/PAU TBS 2013
System Improvement Provisions of the Affordable Care Act
Access to Essential Medicines
Pharmacy Benefit Manager
National Medicines Policies
Presentation transcript:

Jordan Food & Drug Administration

Pharmaceutical Policy Studies Workshop RUD Unit Plan for RUD Unit

Workshop First day presentations/Second day group discussion. Topic for discussion: Should there be a National RUD Unit to progress RUD issues in Jordan? If No, how else might RUD be coordinated and facilitated? If Yes, outline five major strategies for the RDU Unit.

Then… In what Institution (s) should it reside? What should be the administrative structure? Where might the funding come from? What is the RUD Unit's mandate?

Group 1 1- Updating and adopting NDF for EDL. 2- Standard Treatment Guidelines. 3- Drug and Therapeutic Committee Activities. 4- JPA activity related in RUD. 5- Regulation of pharmaceutical promotion.

Group 2 1- National Treatment Guidelines. 2- Essential Drug List. 3- Drug and Therapeutics Committee. 4- Monitoring and Quality Assurance. 5- Continuous Education.

Group 3 1. Development of evidence-based STG 2. Adopt and implement (EDL) and (JNF) 3. Create DTC in all hospitals 4. Ensure training and CE consumer awareness of RUD 5. Establish a health information system 6. Development of ethical code for drug promotion (depending on WHO ethical code)

Group 4 1. Adopt or develop and implement NDF, EDL 2. Adopt or develop STG 3. Establish a research and support unit for RUD 4. Establish a national drug information and pharmacovigilance centre 5. Implement pharmaceutical care program and educate and promote RUD

Group 5 1- Development of a National Formulary 2- Development of Essential Drug List 3- Development of Standard Treatment Guidelines 4- Development of Pharmaceutical care program 5- Development of Monitoring and field study systems

RUD Unit Structure a. In what Institution should it reside? b. What should be the administrative structure? c. Where does the funding come from? d. What is the RUD Unit's mandate?

Group 1 Independent Unit / JPA Department under high level boards of directors Initially international funding, later government public sector funding

Group 2 Independent: either JFDA or MOH Board of directors with representatives from MOH, JFDA, RMS, Director Office Funds MOH / JFDA RMS Powers to implement different functions

Group 3 Independent unit / JFDA Public and private sector International donors Costs percentage of registration fees Support MoF Mandate Outside the MoH

Group 4 JFDA Head of the unit / Directorate plus4 major units. Stakeholders MoH / JFDA / International community.

Group 5 Independent / JFDA Administratively independent International institutions and / or within the health care public budget Private sector but with some flexibility in the public sector

Now we are on the phase of implementing all what have been mentioned. Starting with forming a Steering Committee of 10 DM and holding a meeting to discuss all the previous recommendations.

The Administration does believe that someone has to take the first step if not the JFDA who else???

Thank You All